Tvardi Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TVRD Nasdaq 2836 tvarditherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tvardi Therapeutics, Inc.

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 8th, 2026 2:05 pm
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights - Jan 8th, 2026 6:00 am
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nov 18th, 2025 7:55 am
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - Nov 18th, 2025 6:00 am
Tvardi: Q3 Earnings Snapshot - Nov 13th, 2025 2:08 pm
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update - Nov 13th, 2025 2:01 pm
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - Nov 4th, 2025 6:00 am
Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now - Oct 28th, 2025 7:55 am
Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround - Oct 16th, 2025 7:35 am
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Oct 14th, 2025 9:24 am
AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance - Oct 14th, 2025 5:53 am
Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results - Oct 14th, 2025 2:10 am
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis - Oct 13th, 2025 5:30 am
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26% - Oct 11th, 2025 6:00 am
Tvardi Therapeutics (NASDAQ:TVRD) Is In A Good Position To Deliver On Growth Plans - Aug 31st, 2025 7:26 am
Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference - Aug 21st, 2025 6:00 am
Tvardi: Q2 Earnings Snapshot - Aug 14th, 2025 4:17 pm
Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update - Aug 14th, 2025 2:01 pm
This ‘Strong Buy’ Stock Could Be the Next Big Biotech Breakout - Jul 18th, 2025 5:30 am
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - Jul 15th, 2025 6:00 am